China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $131K invested in China SXT Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 5 closing their positions.
8.88% more ownership
Funds ownership: 0.28% → 9.16% (+8.9%)
75% less capital invested
Capital invested by funds: $524K → $131K (-$393K)
80% less funds holding
Funds holding: 5 → 1 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$241K |
| 2 |
Invesco
Atlanta,
Georgia
|
-$137K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$85.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$36.4K |
| 5 |
VF
Virtu Financial
New York
|
-$20K |
SXTC Hedge Fund Activity: Q1 2026 in Review
1 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2026, worth a combined $131K — down 75% from $524K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SXTC and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.01M. The largest seller was Citadel Advisors, exiting entirely with an estimated $241K sold.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q1 2026, down from 5 in Q4 2025.
- Funds reported $131K of China SXT Pharmaceuticals stock for Q1 2026, down 75% quarter-over-quarter.
- 1 fund opened new China SXT Pharmaceuticals positions in Q1 2026 and 5 closed out, a net change of -4 holders.
- The largest China SXT Pharmaceuticals buyer in Q1 2026 was Sabby Management, an estimated $2.01M added.
- The largest China SXT Pharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $241K sold.
Based on aggregated 13F filings for Q1 2026.